16 completed, 5 unknown, 2 recruiting, 1 active not recruiting. 10 Phase 3, 8 Phase 2, 5 Phase 1, 4 Phase 4, 2 Not applicable.
Follow Pneumococcal Vaccines: new trials by email Literature Review of Pneumococcal Vaccines trials Research Report on Pneumococcal Vaccines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Opportunistic Pneumococcal Immunisation Trial in MALnutrition Pneumococcal conjugate vaccine, Typhoid conjugate vaccine - Severe Acute Malnutrition in Childhood, Pneumococcal Disease | Phase 4 | Recruiting | Nick Fancourt | 214 | 2026-01-16 | 2026-10-08 |
| Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans 21-valent pneumococcal conjugate vaccine - Pneumococcal Vaccines, Immunosuppression | Phase 4 | Not yet recruiting | VA Sierra Nevada Health Care System | 45 | 2026-01-01 | 2025-08-14 |
| Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine 26-Valent pneumococcal conjugate vaccine, 23-Valent pneumococcal polysaccharide vaccine, 13-Valent pneumococcal conjugate vaccine - Pneumococcal Vaccines | Phase 1 / Phase 2 | Completed | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 450 | 2025-07-17 | 2026-03-30 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31 - Pneumococcal Vaccines | Phase 2 | Active not recruiting | Vaxcyte, Inc. | 900 | 2024-11-25 | 2026-05-15 |
| A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine pneumococcal disease prevention - Pneumococcal Vaccines, Pneumococcal Infections | Phase 3 | Recruiting | Beijing Minhai Biotechnology Co., Ltd | 500 | 2024-11-01 | 2025-03-24 |
| Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine - Pneumococcal Vaccines | Phase 1 / Phase 2 | Completed | Vaxcyte, Inc. | 1015 | 2023-11-08 | 2025-07-28 |
| Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age Enhanced reminders, Standard CANImmunize notifications - Pneumococcal Vaccines, Immunization Coverage | Not applicable | Unknown | Ottawa Hospital Research Institute | 700 | 2023-11-07 | 2024-04-09 |
| Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine IVT PCV-25 Formulation A, IVT PCV-25 Formulation B, IVT PCV-25 Formulation C - Pneumococcal Vaccines | Phase 2 | Completed | Inventprise Inc. | 220 | 2023-10-25 | 2026-03-17 |
| Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil. 12-Valent Pneumococcal Conjugate Vaccine - Pneumococcal Vaccines | Phase 3 | Unknown | Maria de Lourdes de Sousa Maia, MD | 2400 | 2023-08-28 | 2023-02-10 |
| Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24 - Pneumococcal Vaccines | Phase 2 | Completed | Vaxcyte, Inc. | 802 | 2023-03-29 | 2025-09-11 |
| Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine IVT PCV-25, PCV 20 - Pneumococcal Vaccines | Phase 1 | Completed | Inventprise Inc. | 65 | 2022-09-28 | 2023-08-30 |
| Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults 24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine - Pneumococcal Vaccines | Phase 2 | Completed | Vaxcyte, Inc. | 207 | 2022-06-15 | 2024-10-09 |
| Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults 24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine - Pneumococcal Vaccines | Phase 1 / Phase 2 | Completed | Vaxcyte, Inc. | 835 | 2022-02-22 | 2024-04-18 |
| Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Vaccine - Safety, Immunogenicity, Vaccine | Phase 4 | Unknown | Centers for Disease Control and Prevention, China | 3000 | 2021-10-08 | 2022-03-28 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) V114, Prevnar 13™, RotaTeq™ - Pneumococcal Infections, Pneumococcal Vaccines | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1720 | 2019-06-19 | 2023-07-28 |
| Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses PCV-13, PPSV-23 - HIV, Pneumococcal Infections | Not applicable | Unknown | University of Colorado, Denver | 60 | 2014-08-01 | 2020-11-18 |
| 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants. 13-valent pneumococcal conjugate vaccine - Pneumococcal Vaccines | Phase 3 | Completed | Pfizer | 500 | 2014-01-01 | 2015-03-13 |
| Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam PCV10, PCV13 - Pneumococcal Vaccines | Phase 2 / Phase 3 | Completed | Murdoch Childrens Research Institute | 1400 | 2013-09-30 | 2022-09-14 |
| A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine - Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine | Phase 3 | Completed | Pfizer | 764 | 2012-06-01 | 2013-09-20 |
| Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults Placebo, SPWCV+Alum 100 mcg, SPWCV+Alum 600 mcg - Pneumococcal Vaccines | Phase 1 | Completed | PATH Vaccine Solutions | 42 | 2012-02-01 | 2014-06-05 |
Showing 20 of 25. Sign in to see all of them.
Pneumococcal Infections (6) · Pneumonia (3) · HIV Infections (1) · Influenza, Human (1)
Infections (8) · Bacterial Infections (6) · Bacterial Infections and Mycoses (6) · Gram-Positive Bacterial Infections (6) · Streptococcal Infections (6) · Respiratory Tract Diseases (4) · Respiratory Tract Infections (4) · Lung Diseases (3) · RNA Virus Infections (2) · Virus Diseases (2) · Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1)
13-valent pneumococcal vaccine (3) · 23-valent pneumococcal capsular polysaccharide vaccine (3) · Pneumococcal Vaccines (3) · Heptavalent Pneumococcal Conjugate Vaccine (2) · 10-valent pneumococcal conjugate vaccine (1) · Acetaminophen (1) · Chickenpox Vaccine (1) · Hepatitis A Vaccines (1) · Hiberix (1) · Ibuprofen (1) · PHiD-CV vaccine (1) · Recombivax HB (1) · RotaTeq (1) · Vaccines (1) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (1)
Vaxcyte, Inc. (5) · Pfizer (4) · Inventprise Inc. (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Beijing Minhai Biotechnology Co., Ltd (1) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1) · Centers for Disease Control and Prevention, China (1) · Hospital Universitari Son Dureta (1) · Maria de Lourdes de Sousa Maia, MD (1) · Merck Sharp & Dohme LLC (1) · Murdoch Childrens Research Institute (1) · Nick Fancourt (1) · Ottawa Hospital Research Institute (1) · PATH Vaccine Solutions (1) · University of Colorado, Denver (1)
United States (9) · Canada (3) · China (2) · Poland (2) · Puerto Rico (2) · Indonesia (1) · Japan (1) · Spain (1) · Sweden (1) · Thailand (1) · The Gambia (1) · Timor-Leste (1) · Turkey (Türkiye) (1) · Vietnam (1)
Edward K Mulholland, MBBS, FRACP (1) · Edward N Janoff, MD (1) · Joanne Langley, MD, MSc, FRCPC (1) · Royce Morrison, M.D. (1) · Sybil Tasker, MD, MPH, FIDSA (1)
PMID 41576705, PMID 20299956, PMID 21335032, PMID 24606865, PMID 28262330, PMID 28479175, PMID 29884695, PMID 30592459, PMID 30975525, PMID 31895881, PMID 33745731, PMID 34171233, PMID 36621410, PMID 36785850, PMID 37846456, PMID 38061367, PMID 38140184, PMID 39025698, PMID 39229259, PMID 41442837, PMID 41864214
2018 (1), R01AI108479 (1)